CONSOLIDATED FINANCIAL REPORT [IFRS]
for the Three-Month Period Ended June 30, 2024

August 2, 2024
Eisai Co., Ltd.

Stock exchange listing: Tokyo Stock Exchange (TSE)TSE Code: 4523
URL: https://www.eisai.com
Representative: Haruo Naito, Representative Corporate Officer & CEO
Contact: Sayoko Sasaki, Vice President, Corporate Communications
Telephone: +81-3-3817-5120
Expected date of dividend payment commencement: —Preparation of supplementary explanatory material: Yes
Financial results briefing held: Yes(Figures are rounded to the nearest million yen)

1. Consolidated Financial Results for the Three-Month Period Ended June 30, 2024
(1) Consolidated Operating Results(Percentage figures show year on year change)
RevenueThree-month
period ended
June 30,
2024
Three-month
period ended
June 30,
2023

Profit before
income taxes

Operating profit

Profit for theperiodProfit for theperiod attributableto owners of theparentComprehensive
income for theperiod(¥ million)(%)(¥ million)(%)(¥ million)(%)(¥ million)(%)(¥ million)(%)(¥ million)(%)

189,029-4.0

13,407-48.5

15,969-43.5

11,510-44.9

10,581-48.0

52,625-23.1

196,935

6.9

26,027250.1

28,285191.0

20,901-25.3

20,339-24.4

68,423-14.2

Earnings per share attributableto owners of the parent (basic)
Three-month period
ended June 30, 2024
Three-month period
ended June 30, 2023

Earnings per share attributableto owners of the parent (diluted)

(¥)

(¥)

36.95

—

70.92

—

(2) Consolidated Financial Position(¥ million)(¥ million)(¥ million)

Ratio of equity
attributable toowners of the parent(%)

As of June 30, 2024

1,420,247

919,696895,766

63.1

3,137.28

As of March 31, 2024

1,393,799

898,975

875,61462.8

3,052.99

Total assets

Total equity

Equity attributable toowners of the parent

Equity per share
attributable toowners of the parent(¥)

2. Dividends
Annual dividend per share
End of Q1

End of Q2

End of Q3(¥)
FY 2023—

FY 2024—(¥)

FY 2024 (Forecast)End of FY
(¥)

Total
(¥)

(¥)

80.00

—

80.00

160.00

80.00

—

80.00

160.00(Note) Revisions to the latest dividend forecast: No

3. Consolidated Financial Forecast for Fiscal 2024 (April 1, 2024 – March 31, 2025)
Revenue

FiscalYear

Operating profit

Profit before
income taxes(Percentage figures show year on year change)
Profit for the year
Earnings per share
Profit for theattributable toattributable toyear
owners of theowners of theparentparent (basic)(¥ million)(%)(¥ million)(%)(¥ million)(%)(¥ million)(%)(¥ million)

(%)

(¥)

754,000

1.7

53,5000.2

60,000-2.944,5001.6

43,0001.4

152.50(Note) 1. Revisions to the latest financial forecast: No
2. A resolution to acquire the Company’s own shares was adopted at the meeting of the Board of Directors held on May 15, 2024.
The impact of the acquisition of the Company’s own shares is taken into account in the “earnings per share attributable toowners of the parent (basic)” in the consolidated financial forecast for the fiscal year ending March 31, 2025.

* Explanatory Notes(1) Changes in number of significant subsidiaries during the period (changes in specified subsidiaries resulting
in a change in scope of consolidation): No(2) Changes in accounting policies and accounting estimates:
1) Changes in accounting policies required by IFRS: Yes
2) Changes in accounting policies other than 1): No
3) Changes in accounting estimates: No(3) Number of shares issued (common shares):
1) Number of shares issued(including treasury shares)

As of June 30, 2024

296,566,949

As of March 31, 2024

296,566,949

2) Number of treasury shares

As of June 30, 2024

10,813,936

As of March 31, 2024

9,531,401

3) Weighted average numberof shares outstanding

For the three-month
period ended June 30,
2024

286,347,412

For the three-month
period ended June 30,
2023

286,795,349

The Company’s shares held through a trust (230,257 shares) are not included in the number of treasury shares as of theend of the period, but are included in the average number of shares outstanding as treasury shares that are deductedfrom the calculation of earnings per share.

* Review of attached Interim Consolidated Financial Statements by independent auditors: No* Explanation concerning the appropriate use of results forecast and other special instructions:(Caution concerning forward-looking statements)
Materials and information provided in this financial disclosure may contain “forward-looking statements” based on
expectations, business goals, estimates, forecasts and assumptions that are subject to risks and uncertainties as of the
publication date of these materials. Accordingly, actual outcomes and results may differ materially from these statements
depending on a number of important factors. Please refer to the page 7 for details with regard to the assumptions and otherrelated matters concerning the consolidated financial forecast.
(Methods for obtaining supplementary materials and content of financial results disclosure meeting)
Supplementary materials are attached to this financial report. The Company plans to hold a financial results disclosure
meeting for institutional investors and securities analysts on Friday, August 2, 2024. The handouts for the disclosure meeting
will be made available on the Company’s website.

Supplemental Materials: Table of Contents
1. Qualitative Information regarding Financial Results for the Period(Page)(1) Operating Results･･･････････

2(2) Financial Position･･･････････

4(3) Research & Development Pipeline, Alliances, and Other Events･･･････････

5(4) Information on Outlook for the Future including Financial Forecast･･･････････

7(1) Condensed Interim Consolidated Statement of Income･･･････････

8(2) Condensed Interim Consolidated Statement of Comprehensive Income･･･････････

9(3) Condensed Interim Consolidated Statement of Financial Position･･･････････

10(4) Condensed Interim Consolidated Statement of Changes in Equity･･･････････

12(5) Condensed Interim Consolidated Statement of Cash Flows･･･････････

14(Going Concern)･･･････････

15(Changes in Accounting Policies)･･･････････

15(Segment Information)･･･････････

16(Consolidated Statement of Income)･･･････････

17(Significant Subsequent Events)･･･････････

17

2. Condensed Interim Consolidated Financial Statements and Major Notes(6) Notes to Condensed Interim Consolidated Financial Statements

11．Qualitative Information regarding Financial Results for the Period(1) Operating Results[Revenue and Profit]〇 Eisai Co., Ltd. (“the Company”) and its affiliates (collectively referred to as “the Group”)
recorded the following consolidated financial results for the three-month period ended June30, 2024.

(¥billion)
Three-month period
ended June 30, 2023

Three-month period
ended June 30, 2024

Year on yearchange (%)

Revenue

196.9

189.0

96.0

Cost of sales

43.9

39.8

90.5

Gross profit

153.0

149.3

97.6

Selling, general andadministrative expenses

86.1

99.5

115.6

Research and development
expenses

41.1

41.7

101.4

Other income

0.6

5.5

861.9

Operating profit

26.0

13.4

51.5

Profit before income taxes

28.3

16.0

56.5

Profit for the period

20.9

11.5

55.1

Profit for the period attributableto owners of the parent

20.3

10.6

52.0

〇 While anticancer agent Lenvima, insomnia treatment Dayvigo and Alzheimer’s disease (AD)treatment Leqembi continued to grow, revenue decreased due to receipt of an upfront
payment in the same period of the previous fiscal year for transfer of future economic rights
for elacestrant, a selective estrogen receptor degrader. Revenue of pharmaceuticalbusiness came to ¥186.6 billion (102.7% year on year).
〇 Regarding revenue from major products, revenue for Lenvima, Dayvigo, antiepileptic agent
Fycompa and Leqembi was ¥83.5 billion (118.1% year on year), ¥12.1 billion (129.0% year
on year), ¥7.4 billion (91.1% year on year) and ¥6.3 billion (¥0.1 billion in the same periodof the previous fiscal year), respectively.
〇 Selling, general and administrative expenses increased due to increase in selling expenses
for Leqembi and shared profit paid to Merck & Co., Inc., Rahway, NJ, USA following
Lenvima’s revenue growth, as well as depreciation of the Japanese yen.
〇 While efficiency was enhanced through the partnership model, research and development
expenses increased due to aggressive resource investment in important projects such as
Leqembi and the depreciation of the Japanese yen.
〇 Following the end of the global strategic collaboration with Bristol Myers Squibb (U.S.) for
the antibody drug conjugate farletuzumab ecteribulin, other income increased due to therecording of ¥4.8 billion as reversal profit of the deposit Eisai previously received from
Bristol Myers Squibb at the time of entering into the collaboration agreement.

2

〇 As a result of the above, operating profit decreased, and segment profit of pharmaceuticalbusiness came to ¥91.2 billion (102.3% year on year).

[Performance by Segment](Revenue for each segment indicates revenue from external customers)
The Group’s business is comprised of pharmaceutical business and other business. The
pharmaceutical business is organized into the following five reporting segments in this report:
Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia andOceania), and Asia and Latin America (primarily South Korea, Taiwan, India, ASEAN, Central
and South America). In order to more accurately reflect the actual condition of management,
expenses associated with medical activities in each reporting segment which were previously
included in research and development expenses, will be reflected in the profits of each segmentfrom this fiscal year. This change has been reflected in Segment Information for the fiscal year
ended March 31, 2024.

<Japan pharmaceutical business>〇 Total revenue came to ¥52.8 billion (81.9 % year on year), with a segment profit of ¥19.1
billion (85.6% year on year). Breakdown of revenue was ¥47.5 billion (80.8% year on year)
from prescription medicines and ¥5.3 billion (93.1% year on year) from OTC and others.
Revenue and profit decreased mainly due to expiration of the co-promotion agreement for
fully human anti-TNF-α monoclonal antibody Humira in June 2023.
〇 Regarding revenue by product, from neurology products, revenue for Dayvigo achieved
significant growth coming to ¥10.2 billion (125.0% year on year). Revenue for Fycompaachieved growth coming to ¥1.9 billion (107.0% year on year). Revenue for Leqembi, which
was launched in December 2023, came to ¥1.5 billion. Among oncology products, revenue
for Lenvima and anticancer agent Halaven came to ¥3.4 billion (82.2% year on year) and¥1.9 billion (88.4% year on year), respectively. Revenue for a JAK (Janus kinase) inhibitor
Jyseleca and chronic constipation treatment Goofice both achieved significant growth
coming to ¥3.5 billion (116.7% year on year) and ¥2.0 billion (111.9% year on year),respectively. In OTC and others, revenue for Chocola BB Group came to ¥3.5 billion (94.4%
year on year).
〇 An injection formulation of Fycompa was launched in April 2024.

<Americas pharmaceutical business>〇 Total revenue came to ¥69.8 billion (128.4% year on year), with a segment profit of ¥41.2
billion (121.5% year on year).
〇 Regarding revenue by product, from neurology products, revenue for Leqembi and Dayvigo
both achieved significant growth coming to ¥4.6 billion (¥0.1 billion in the same period of
the previous fiscal year) and ¥1.5 billion (141.1% year on year), respectively. Among
oncology products, Lenvima earned ¥59.8 billion (124.2% year on year) achieving
significant growth. Revenue for Halaven came to ¥2.7 billion (92.3% year on year).

3

<China pharmaceutical business>〇 Revenue totaled ¥30.2 billion (95.6% year on year), with a segment profit of ¥15.6 billion(84.3% year on year).
〇 Regarding revenue by product, revenue for Lenvima came to ¥7.0 billion (101.8% year onyear) achieving growth. Revenue for vertigo and equilibrium disturbance treatment Merisloncame to ¥4.5 billion (120.8% year on year) achieving significant growth. Revenue for
peripheral neuropathy treatment Methycobal came to ¥3.0 billion (79.2% year on year).
〇 Leqembi was launched in China in June 2024.

<EMEA pharmaceutical business>〇 Revenue totaled ¥19.5 billion (104.5% year on year), with a segment profit of ¥8.8 billion(100.7% year on year).
〇 Regarding revenue by product, from neurology products, revenue for Fycompa came to¥4.0 billion (130.3% year on year) achieving significant growth. Among oncology products,
revenue for Lenvima/Kisplyx achieved growth coming to ¥10.1 billion (111.3% year on year).
Revenue for Halaven came to ¥2.4 billion (78.9% year on year).

<Asia and Latin America pharmaceutical business>〇 Revenue totaled ¥14.3 billion (112.3% year on year), with a segment profit of ¥6.5 billion(114.5% year on year).
〇 Regarding revenue by product, Lenvima achieved significant growth, recording revenue of¥3.3 billion (127.3% year on year). Revenue for Aricept, a treatment for Alzheimer’s disease
dementia, achieved growth coming to ¥3.8 billion (118.4% year on year).
〇 Parkinson’s disease treatment Equfina was launched in Malaysia in May 2024.

(2) Financial Position[Assets, Liabilities, and Equity]〇 Total assets as of the end of the period amounted to ¥1,420.2 billion (up ¥26.4 billion fromthe end of the previous fiscal year). Assets of overseas consolidated subsidiaries increased
due to the depreciation of the Japanese yen. In addition, inventories increased due toproceeding the production of Leqembi and others.
〇 Total liabilities as of the end of the period amounted to ¥500.6 billion (up ¥5.7 billion fromthe end of the previous fiscal year). While other financial liabilities decreased following
decrease in deposit received, short-term borrowings increased.
〇 Total equity as of the end of the period amounted to ¥919.7 billion (up ¥20.7 billion from theend of the previous fiscal year). While the Company acquired its own shares, exchange
differences on translation of foreign operations increased following the depreciation of theJapanese yen.
〇 As a result of the above, the ratio of equity attributable to owners of the parent was 63.1%(up 0.2 percentage points from the end of the previous fiscal year).

4[Cash Flows]〇 Net cash from operating activities amounted to an outflow of ¥8.6 billion (an inflow of ¥12.6
billion in the same period of previous fiscal year). Working capital increased mainly due toincrease in inventories for Leqembi and others, as well as payment of accrued expenses
to partners and others.
〇 Net cash used in investing activities amounted to an inflow of ¥3.6 billion (an outflow of¥11.6 billion in the same period of previous fiscal year). The Company received an upfront
payment for divestiture of sales rights in March 2024 for some products in France.
〇 Net cash used in financing activities amounted to an outflow of ¥11.9 billion (down ¥3.6
billion from the same period of previous fiscal year) mainly due to acquisition of own sharesand payment of dividends.
〇 As a result of the above, cash and cash equivalents as of the end of the period stood at¥303.9 billion (down ¥0.7 billion from the end of the previous fiscal year). Free cash flow
(cash flow from operating activities excluding capital expenditures) for the year was an
outflow of ¥5.0 billion.

(3) Research & Development Pipeline, Alliances, and Other Events[Status of Ongoing Research & Development Pipelines]〇 Anticancer agent Lenvima (lenvatinib, jointly developed with Merck & Co., Inc., Rahway, NJ,USA)Approved as a monotherapy for use in the treatment of thyroid cancer and hepatocellular
carcinoma (first-line) mainly in Japan, the United States, Europe, China and Asia.


Approved as a monotherapy for use in the treatment of unresectable thymic carcinoma



in Japan.
Approved in combination with everolimus for use in the treatment of renal cell carcinoma(second-line) mainly in the United States, Europe and Asia.



Approved in combination with pembrolizumab, Merck & Co., Inc., Rahway, NJ, USA’santi-PD-1 therapy, for use in the treatment of renal cell carcinoma (first-line) andendometrial carcinoma (following prior systemic therapy) mainly in Japan, the UnitedStates, Europe and Asia.

Regarding studies of the agent in combination with pembrolizumab, respective Phase III
studies for hepatocellular carcinoma (first-line, in combination with transcatheter arterial
chemoembolization),

esophageal

carcinoma(first-line,

incombinationwithchemotherapy), and gastric cancer (first-line, in combination with chemotherapy), as well
as a Phase II study for head and neck cancer (second-line) are underway mainly in the
United States and Europe.
〇 AD treatment Leqembi (lecanemab, jointly developed with Biogen Inc. (U.S.))

In addition to being approved as a treatment for early AD in Japan, the United States
and China, the agent was approved in South Korea in May 2024, and in Hong Kong andIsrael in July 2024. Applications have been filed mainly in Europe, Canada, Great Britain,
and Australia.

Regarding a subcutaneous injection formulation, the rolling submission of a Biologics
License Application (BLA) for subcutaneous autoinjector for weekly maintenance dosing5was initiated in the United States under the Fast Track status in May 2024.
A Supplemental Biologics License Application (sBLA) for monthly intravenous

maintenance dosing was accepted in the United States in June 2024.
In July 2024, the Committee for Medicinal Products for Human Use (CHMP) of theEuropean Medicines Agency adopted a negative opinion on the agent’s Marketing
Authorization Approval (MAA). Eisai is initiating process for seeking a re-examination ofthe CHMP’s opinion.
AHEAD 3-45 (Phase III study) for preclinical (asymptomatic) AD is underway in countries
including Japan, the United States and Europe. In this study, the agent has been
selected by the Alzheimer's Clinical Trials Consortium (ACTC) as a treatment to beevaluated.

〇 Insomnia treatment Dayvigo (lemborexant)

Approved for the treatment of insomnia mainly in Japan, the United States and Asia.



An application seeking approval for the treatment of insomnia has been filed in China.

〇 Antiepileptic agent Fycompa (perampanel)

Approved as an adjunctive therapy for use in the treatment of partial-onset seizures
mainly in Japan, Europe, China and Asia. Approved as a monotherapy in Japan and
China.



Approved as an adjunctive therapy for use in the treatment of primary generalized tonicclonic seizures mainly in Japan, Europe and Asia. Indication expansion as an adjunctive
therapy for use in the treatment of primary generalized tonic-clonic seizures in patientswith epilepsy 12 years of age and older was approved in China in April 2024.

[Major Alliances and Agreements]○ In June 2024, Eisai’s consolidated subsidiary EA Pharma Co., Ltd. (Tokyo) entered into alicensing agreement granting Ensho Therapeutics, Inc. (U.S.) exclusive rights to develop,
manufacture, and commercialize a novel inflammatory bowel disease treatment(development code: EA1080) and a portfolio of other antagonists globally, excluding Japan,
China, Hong Kong, Macau, South Korea, Taiwan, and ASEAN.
○ In June 2024, Eisai agreed to end its global strategic collaboration with Bristol Myers Squibb
for the co-development and co-commercialization of the antibody drug conjugate
farletuzumab ecteribulin, and moved to solo global development and commercialization of
the agent.
○ In July 2024, Eisai entered into a license agreement regarding the development andcommercialization rights for the antifungal agent fosravuconazole for fungal diseases(excluding mycetoma and its associated conditions) in 10 ASEAN nations, Australia, New
Zealand, South Korea and Taiwan with Sato Pharmaceutical Co., Ltd. (Tokyo).
○ In July 2024, Eisai entered into a business alliance agreement with EcoNaviSta, Inc. (Tokyo)
with the aim of building an ecosystem in the area of dementia. Under the agreement, bothcompanies will mainly promote a proof-of-concept experiment to encourage awareness ofchanges in cognitive function among residents in nursing care facilities.

6[Other Events]○ In April 2024, Eisai absorbed and merged with its wholly-owned subsidiary KAN ResearchInstitute, Inc. (Hyogo, Japan) and named it Kobe Research Laboratories.
○ In April 2024, Eisai Europe Ltd., Eisai’s subsidiary in the UK, established pharmaceuticalsales company Eisai Pharmaceuticals Single Person Limited Liability Company as its
wholly-owned subsidiary in Saudi Arabia.
○ In May 2024, a resolution was adopted at a meeting of the Board of Directors to acquire
Eisai’s own shares up to ¥30.0 billion at maximum (ratio to total number of issued shares(excluding treasury shares): 2.3%) and cancel these treasury shares from a long-term ROE
management perspective, taking into consideration Eisai's future financial situation andshareholder returns.

(4) Information on Outlook for the Future including Financial Forecast(April 1, 2024 – March 31, 2025)[Consolidated Financial Forecast]〇 There are no changes to the consolidated financial forecast announced on May 15, 2024.
FY2023

FY2024

Year on year

ForecastchangeRevenue¥741.8 billion¥754.0 billion

101.7%

Operating profit¥53.4 billion¥53.5 billion

100.2%

Profit before income taxes¥61.8 billion¥60.0 billion

97.1%

Profit for the year

¥43.8 billion¥44.5 billion

101.6%¥42.4 billion¥43.0 billion

101.4%¥147.86¥152.50

103.1%

Profit for the year attributable to owners of
the parent
Earnings per share attributable to owners of
the parent (basic)(Assumptions: 1 USD = ¥145.0, 1 EUR = ¥155.0, 1 GBP = ¥180.0, 1 RMB = ¥20.4)[Forecasts and Risk Factors]
The materials and information provided in this announcement include current forecasts, targets,
evaluations, estimates, assumptions that are accompanied by risks, and other matters that are
based on uncertain factors. Accordingly, it is possible that actual results will deviate significantly
from forecasts, etc., due to changes to a variety of factors. These risks and uncertainties include
general industry and market conditions, fluctuation of interest rates and currency exchange
rates, and other aspects of economic conditions in Japan and internationally.
For further details on risks and uncertainties that could cause significant fluctuations in the
results of the Group or have a material effect on investment decisions, please refer to the “Risk
Factors” section of the Annual Securities Report in the previous fiscal year. However, these do
not cover all of the risks and uncertainties faced by the Group, and it is possible that they will
be affected in the future by other factors that cannot be foreseen, or are not deemed to beimportant, at this point in time.
These are judgments as of the time of the announcement, and statements in the text regarding
the future are not guarantees that they will occur or be achieved.
72. Condensed Interim Consolidated Financial Statements and Major Notes(1) Condensed Interim Consolidated Statement of Income(Millions of yen)Three-month period
ended June 30, 2024

Three-month period
ended June 30, 2023

Revenue

189,029

196,935

Cost of sales(39,757)(43,920)Gross profit

149,272

153,015

Selling, general and administrative expenses(99,544)(86,083)

Research and development expenses(41,736)(41,147)

Other income

5,534

642

Other expenses

(118)

(400)

Operating profit

13,40726,027

Financial income

3,277

2,788

Financial costs

(715)

(530)

15,96928,285(4,459)(7,385)

11,51020,901

10,581

20,339

929

561

36.95

70.92

Profit before income taxes

Income taxes
Profit for the period

Profit for the period attributable to
Owners of the parent
Non-controlling interests

Earnings per share
Basic (yen)8(2) Condensed Interim Consolidated Statement of Comprehensive Income(Millions of yen)Three-month period
ended June 30, 2024

Three-month period
ended June 30, 2023

11,51020,901

Financial assets measured at fair value through othercomprehensive income (loss)

116

3,470

Subtotal

116

3,470

40,85643,889142

163

Subtotal

40,99944,052

Total other comprehensive income (loss), net of tax

41,11547,522

52,62568,42351,68467,820941

602

Profit for the period

Other comprehensive income (loss)
Items that will not be reclassified to profit or loss

Items that may be reclassified subsequently to profit or loss
Exchange differences on translation of foreign operations
Cash flow hedges

Comprehensive income (loss) for the period

Comprehensive income (loss) for the period attributable to
Owners of the parent
Non-controlling interests9(3) Condensed Interim Consolidated Statement of Financial Position(Millions of yen)
As ofJune 30, 2024

As ofMarch 31, 2024

AssetsNon-current assets
Property, plant and equipment

165,352

164,894

Goodwill

251,317236,366

Intangible assets

82,97185,493

Other financial assets

59,62057,674

Other assets

25,871

25,564

Deferred tax assets

101,894

100,826

Total non-current assets

687,025

670,816

Inventories

190,601

174,651

Trade and other receivables

205,355

217,208

947

445

Other assets

32,38326,001

Cash and cash equivalents

303,935

304,678

Total current assets

733,222722,983

1,420,247

1,393,799

Current assets

Other financial assets

Total assets

10

(Millions of yen)
As ofJune 30, 2024

As ofMarch 31, 2024

EquityEquity attributable to owners of the parent
Share capital

44,98644,986

Capital surplus

78,772

78,863

Treasury shares(42,090)(33,612)Retained earnings

514,225

526,490

Other components of equity

299,873

258,886

Total equity attributable to owners of the parent

895,766

875,614

Non-controlling interests

23,93023,361

Total equity

919,696

898,975

Borrowings

134,786

134,773

Other financial liabilities

39,481

38,548Provisions

1,459

1,413

Other liabilities

13,006

14,915801

704

189,533

190,352

Borrowings

47,54824,632

Trade and other payables

77,79872,249Other financial liabilities

16,60834,250

Income taxes payable

6,051

8,718

Provisions

30,46331,195

Other liabilities

132,550

133,428

Total current liabilities

311,018

304,472

500,551494,825

1,420,247

1,393,799

Liabilities
Non-current liabilities

Deferred tax liabilities
Total non-current liabilities

Current liabilities

Total liabilities
Total equity and liabilities11(4) Condensed Interim Consolidated Statement of Changes in Equity
For the three-month period ended June 30, 2024
(Millions of yen)
Equity attributable to owners of the parent
Other componentsof equity
Share capital

Financial assets
measured at fairvalue throughothercomprehensive
income (loss)

Capital surplus

Treasury shares

Retained earnings

44,98678,863(33,612)526,490

－

－

－

－

10,581

－

－

－

－

－

116

－

－

－

10,581

116

Dividends－－－(22,963)－

Acquisition of treasury shares－－(8,479)－－Reclassification

－

－

－

116

(116)

Other

－

(91)

－

－

－

－

(91)

(8,479)(22,847)(116)

44,98678,772(42,090)514,225－

As of April 1, 2024
Profit for the period
Total other comprehensive
income (loss)
Comprehensive income (loss)
for the period

Total transactions with owners
As of June 30, 2024

Equity attributable to owners of the parent
Other components of equity
Exchangedifferences ontranslation offoreign
operations
As of April 1, 2024
Profit for the period

Total othercomponentsof equity

Cash flow
hedgesTotal equity
attributable toowners of theparentNon-controllinginterests

Total equity

258,85532

258,886

875,614

23,361

898,975－－－

10,581929

11,510Total other comprehensive
income (loss)

40,844

142

41,103

41,103

12

41,115Comprehensive income (loss)
for the period

40,844

142

41,10351,684941

52,625

Dividends－－－(22,963)(462)(23,425)

Acquisition of treasury shares

－

－

－

(8,479)－(8,479)Reclassification

－

－

(116)

－

－

－

Other

－

－

－

(91)

91

－

－

－

(116)

(31,532)(371)(31,904)

299,699174

299,873895,766

23,930919,696

Total transactions with owners
As of June 30, 2024

12

For the three-month period ended June 30, 2023
(Millions of yen)
Equity attributable to owners of the parent
Other componentsof equity
Share capital

Financial assets
measured at fairvalue throughothercomprehensive
income (loss)

Capital surplus

Treasury shares

Retained earnings

44,98678,813(33,638)

522,774－

Profit for the period

－

－

－

20,339－Total other comprehensive
income (loss)

－

－

－

－

3,471

－

－

－

20,3393,471

Dividends－－－(22,952)－

Acquisition of treasury shares

－

－

(8)

－

－

Disposal of treasury shares

－

25

24

－

－

Reclassification

－

－

－

3,471

(3,471)－25

16(19,481)(3,471)

44,98678,838(33,622)523,632－

As of April 1, 2023

Comprehensive income (loss)
for the period

Total transactions with owners
As of June 30, 2023

Equity attributable to owners of the parent
Other components of equity
Exchangedifferences ontranslation offoreign
operations
As of April 1, 2023

Total othercomponentsof equity

Cash flow
hedgesTotal equity
attributable toowners of theparentNon-controllinginterests

Total equity

186,98837

187,024

799,959

22,612

822,571－－－

20,339561

20,901

43,848163

47,481

47,481

41

47,522

43,848163

47,481

67,820602

68,423

Dividends－－－(22,952)(421)(23,373)

Acquisition of treasury shares

－

－

－

(8)

－

(8)

Disposal of treasury shares

－

－

－

49

－

49

Reclassification－－(3,471)

－

－

－

－

－

(3,471)(22,911)(421)(23,332)

230,835200

231,035

844,869

22,793

867,662

Profit for the period
Total other comprehensive
income (loss)
Comprehensive income (loss)
for the period

Total transactions with owners
As of June 30, 2023

13

(5) Condensed Interim Consolidated Statement of Cash Flows(Millions of yen)
For the three-month
period ended June 30,2024

For the three-month
period ended June 30,
2023

Profit before income taxes

15,96928,285

Depreciation and amortization

10,062

9,756

－

2,135

(24,865)(22,346)

Interest and dividends received

2,878

2,195

Interest paid

(604)

(345)

Income taxes paid

(6,063)(2,382)

Other(5,959)(4,658)Net cash from (used in) operating activities(8,581)

12,641

Purchases of property, plant and equipment(3,595)(6,973)Purchases of intangible assets(1,019)(1,594)

9,489

16

(260)

－

(1,143)(3,427)

Proceeds from sale and redemption of financial assets

64

331

Payments of time deposits exceeding three months－(1)

Proceeds from redemption of time deposits exceeding threemonths

0

0

Other

48

52

3,584

(11,596)

22,526

20,100(2)(10,000)

Repayments of lease liabilities(2,508)(2,238)

Payments for acquisition of treasury shares(8,479)(8)

Dividends paid

(22,963)(22,952)

(465)

(363)

(11,890)(15,460)

16,144

16,369

(743)

1,954

Cash and cash equivalents at beginning of period

304,678

267,350

Cash and cash equivalents at end of period

303,935

269,305

Operating activities

Impairment losses(Increase) decrease in working capital

Investing activities

Proceeds from sale of property, plant and equipment andintangible assets
Payments on investments in joint ventures
Purchases of financial assets

Net cash from (used in) investing activities

Financing activities
Net increase (decrease) in short-term borrowings
Repayments of long-term borrowings

Other
Net cash from (used in) financing activities

Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents14(6) Notes to Condensed Interim Consolidated Financial Statements(Going Concern)
Not applicable(Changes in Accounting Policies)
With the exception of the following, all material accounting policies that are applied to these condensed interim
consolidated financial statements for this period are the same as those that were applied to the consolidated financial
statements for the previous fiscal year. None of the following accounting standards and interpretations applied by theGroup has any major impact on the condensed interim consolidated financial statements for this period.
Accounting standards
and interpretations

IAS 1

Presentation of Financial
Statements

IFRS 16

LeasesIAS 7

Statement of Cash FlowsIFRS 7

Financial Instruments:
Disclosures

Mandatory
application(Date ofcommencement)

To be appliedby the Group

January 1, 2024

Fiscal year ending
March 31, 2025

January 1, 2024

Fiscal year ending
March 31, 2025

January 1, 2024

Fiscal year ending
March 31, 2025

15

Description
Clarifying of the classification of
liabilities as current or noncurrent
Clarifying the accounting
treatments of lease liabilities in asale-and-leaseback
Amendments to disclosure of
supplier finance arrangements

(Segment Information)
Reporting segments are units for which the Group can obtain independent financial information and for which top
management undertakes periodic reviews in order to determine the allocation of management resources and evaluate
performance.
The Group’s business is comprised of pharmaceutical business and other business. The pharmaceutical business isorganized into the following five reporting segments in this report: Japan, Americas (North America), China, EMEA(Europe, the Middle East, Africa, Russia and Oceania), and Asia and Latin America (primarily South Korea, Taiwan, India,
ASEAN, Central and South America).
In order to more accurately reflect the actual condition of management, expenses associated with medical activities ineach reporting segment which were previously included in research and development (R&D) expenses, will be reflected in
the profits of each segment from this fiscal year. This change has been reflected in Segment Information for the fiscal year
ended March 31, 2024.
(Millions of yen)Three-month period ended
June 30, 2024
Segment
profit (loss)

RevenueThree-month period ended
June 30, 2023
Segment
profit (loss)

Revenue

Pharmaceutical businessJapan

52,807

19,13464,453

22,342

Americas69,79941,20954,34333,929China

30,173

15,56531,554

18,463

EMEA

19,4998,819

18,663

8,755

Asia and Latin America

14,2736,476

12,705

5,657

186,551

91,202

181,718

89,147

2,478

1,138

15,217

13,155

189,029

92,340196,935

102,302

R&D expenses (Note 2)－(36,531)－(37,127)

Group headquarters’ management
costs and other expenses (Note 3)－(42,402)－(39,148)－

13,407－26,027

Reporting segment total
Other business (Note 1)
Total

Operating profit in the condensed
interim consolidated statement ofincome(Note 1) “Other business” mainly includes the license revenue and pharmaceutical ingredient business of the parent
company.
(Note 2) “R&D expenses” do not include expenses associated with medical activities, which are reflected in each reporting
segment.
(Note 3) “Group headquarters’ management costs and other expenses” are the costs and expenses covering Group-wide
operations which include the amount of other income and expenses, and the amount of profits and expenses
shared under strategic collaborations with partners. For the three-month period ended June 30, 2024, sharedprofit of ¥38,355 million (¥32,312 million for the three-month period ended June 30, 2023) for anticancer agent
Lenvima paid by the Group to Merck & Co., Inc., Rahway, NJ, USA was included in Group headquarters’
management costs and other expenses.

16

(Consolidated Statement of Income)(1) Selling, general and administrative expenses
For the three-month period ended June 30, 2024, the Group recognized shared profit of ¥38,355 million (¥32,312
million for the three-month period ended June 30, 2023) for anticancer agent Lenvima paid by the Group to Merck& Co., Inc., Rahway, NJ, USA as SG&A expenses.
(2) Research and development expenses
For the three-month period ended June 30, 2023, due to the idle operation of some parts of the research facilities
at the Company’s consolidated U.S. subsidiary Eisai Inc.’s former headquarters, for which a lease agreement was
concluded, the Group estimated the recoverable amount of right-of-use assets for those facilities zero, andrecorded impairment losses of ¥2,135 million related to right-of-use assets as R&D expenses.
(3) Other income
For the three-month period ended June 30, 2024, the Company has agreed to end its global strategic
collaboration with Bristol Myers Squibb for the antibody-drug conjugate farletuzumab ecteribulin (development
code: MORAb-202). Following the agreement to end the collaboration, of the unused portion of the deposit
received from Bristol Myers Squibb for the Company's future R&D, the Company recorded ¥4,830 million, which is
not required to be refunded, as other income.
(Significant Subsequent Events)
Not applicable17